疫苗有进展
More promising vaccine results, this time from the University of Oxford and AstraZeneca. In early human testing, the co-developed vaccine showed increased levels of both protective neutralizing antibodies and immune T-cells that target the virus. AstraZeneca rose as much as 10% in London before giving back most of the gains. Earlier, Pfizer and BioNTech reported an initial positive update in their German vaccine study. Shares of Moderna, which is also working on a vaccine, fell.
More promising vaccine results, this time from the University of Oxford and AstraZeneca. In early human testing, the co-developed vaccine showed increased levels of both protective neutralizing antibodies and immune T-cells that target the virus. AstraZeneca rose as much as 10% in London before giving back most of the gains. Earlier, Pfizer and BioNTech reported an initial positive update in their German vaccine study. Shares of Moderna, which is also working on a vaccine, fell.